| Airway remodeling in asthma: update on mechanisms and therapeutic approaches |
25 |
| The asthma-obesity relationship: underlying mechanisms and treatment implications |
16 |
| Artificial intelligence in diagnosis of obstructive lung disease: current status and future potential |
15 |
| Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs |
12 |
| Air pollution in India and related adverse respiratory health effects: past, present, and future directions |
10 |
| Insights about the economic impact of chronic obstructive pulmonary disease readmissions post implementation of the hospital readmission reduction program |
9 |
| Pulmonary phenotypes associated with genetic variation in telomere-related genes |
9 |
| Genetic causes and clinical management of pediatric interstitial lung diseases |
9 |
| Wildfire smoke exposure under climate change: impact on respiratory health of affected communities |
8 |
| Self-management strategies in chronic obstructive pulmonary disease: a first step toward personalized medicine |
8 |
| Precision medicine in asthma: linking phenotypes to targeted treatments |
8 |
| Novel methods for device and adherence monitoring in asthma |
8 |
| Metabolomics in asthma: where do we stand? |
8 |
| Oral corticosteroid-dependent asthma: current knowledge and future needs |
8 |
| Cystic fibrosis survival: the changing epidemiology |
8 |
| The Fatigue Assessment Scale: quality and availability in sarcoidosis and other diseases |
7 |
| Role of microRNAs and exosomes in asthma |
7 |
| Lung transplantation for chronic obstructive pulmonary disease: past, present, and future directions |
7 |
| Lung function trajectories and chronic obstructive pulmonary disease: current understanding and knowledge gaps |
6 |
| Treatable traits of chronic airways disease |
6 |
| New trajectories in the treatment of interstitial lung disease: treat the disease or treat the underlying pattern? |
6 |
| Cardiovascular sequelae of pneumonia |
6 |
| Updates in the diagnosis and treatment of malignant pleural mesothelioma |
6 |
| Sleep and asthma |
6 |
| Home treatment of acute pulmonary embolism: state of the art in 2018 |
6 |
| The lung clearance index as a monitoring tool in cystic fibrosis: ready for the clinic? |
6 |
| Role of imbalance between Th17 and regulatory T-cells in sarcoidosis |
6 |
| Indications for treatment of sarcoidosis |
5 |
| Occupational asthma: clinical phenotypes, biomarkers, and management |
5 |
| Unravelling the complexity of tissue inflammation in uncontrolled and severe asthma |
5 |
| Bronchiectasis in severe asthma: a distinct phenotype? |
5 |
| Obstructive sleep apnea and chronic kidney disease |
5 |
| Methamphetamine and the risk of pulmonary arterial hypertension |
5 |
| Clinical implications of telomere dysfunction in lung fibrosis |
5 |
| Unclassifiable interstitial lung disease: from phenotyping to possible treatments |
5 |
| Imaging biomarkers and staging in IPF |
5 |
| Emerging Gram-negative bacteria: pathogenic or innocent bystanders |
5 |
| Sarcoidosis and autoimmune diseases: differences, similarities and overlaps |
5 |
| Management of nontuberculous mycobacterial pulmonary disease |
5 |
| The right treatment for the right ventricle |
5 |
| Pulmonary hypertension due to interstitial lung disease |
5 |
| Trade-offs in aging lung diseases: a review on shared but opposite genetic risk variants in idiopathic pulmonary fibrosis, lung cancer and chronic obstructive pulmonary disease |
5 |
| Management of the solitary pulmonary nodule |
4 |
| Advances in pathological diagnosis of mesothelioma: what pulmonologists should know |
4 |
| Computed tomography scan contribution to the diagnosis of community-acquired pneumonia |
4 |
| Prevention of anxiety and depression in cystic fibrosis |
4 |
| Pulmonary rehabilitation for patients with acute chronic obstructive pulmonary disease exacerbations: is the evidence strengthening? |
4 |
| Shaping the future of an ultra-rare disease: unmet needs in the diagnosis and treatment of pulmonary alveolar proteinosis |
4 |
| Update on airway stents |
4 |
| Treatment of oncogene-driven non-small cell lung cancer |
4 |
